Search PubMed⌕ Search

PubMed · 10393481

alpha1-adrenoceptors and bladder function.

Abstract

OBJECTIVE: To discuss the role of alpha-adrenoceptors (alpha-ARs) in the control of lower urinary tract function with special emphasis on their importance in the pathologically changed bladder. METHODS: Evaluation of published information. RESULTS: The functional role of the alpha-ARs in the normal detrusor muscle has not been established. Changes in the function of these alpha-ARs may occur in e.g., bladder outflow obstruction, bladder overactivity, and 'neurogenic' bladders. The filling (irritative) symptoms in patients with benign prostatic hyperplasia and outflow obstruction, which are relieved by alpha-AR antagonist treatment, have been associated with bladder dysfunction produced by the obstruction. There is evidence for involvement of alpha-ARs in the spinal control of both the sympathetic, somatic (filling) and parasympathetic (voiding) efferent activity to the lower urinary tract. The beneficial effects of alpha-AR antagonists on filling symptoms, which can be obtained even in the absence of outflow obstruction, give support for the involvement of extravesical, possibly spinal, alpha-ARs in their pathogenesis. CONCLUSIONS: A more complete understanding of the role of alpha-ARs in the control of the normal or functionally changed bladder should be helpful in the development of drugs for treatment of lower urinary tract disorders.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Andersson. 1999. alpha1-adrenoceptors and bladder function.. https://doi.org/10.1159/000052328

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.

INTRODUCTION: Increasing attention has been focused on the use of phytotherapeutic agents to alleviate the symptoms of benign prostatic hyperplasia (BPH) in recent times. The best described and studied phytotherapeutic agent is Serenoa repens (SR). MATERIALS AND METHODS: This prospective study was designed to have 3 arms including SR 320 mg per day (N = 20), Tamsulosin (TAM) 0.4 mg per day (N = 20) and SR + TAM (N = 20) to reveal the superiority or equivalence between these treatment regimens in BPH. RESULTS: The groups were not statistically different with regard to increase in maximal urinary flow rate (Q (max)) and decrease in International Prostate Symptom Score (I-PSS) (P > 0.05). No adverse effect was detected in SR therapy group. CONCLUSION: Treatment of BPH by both SR and TAM seems to be effective alone. None of them had superiority to another and additionally, combined therapy (SR + TAM) does not provide extra benefits. Furthermore SR is a well-tolerated agent that can be used alternatively in the treatment of LUTS due to BPH.

Adrenergic alpha-1 Receptor Antagonists↗

Prazosin increases immobility episodes in taiep rats without changes in the properties of alpha1 receptors.

The taiep rat is a myelin mutant in which immobility episodes (IEs) can be induced in adult males by gripping. EEG recordings during gripping-induced IEs show a rapid eye movement (REM) sleep-like pattern, similar to that reported for narcolepsy-cataplexy suggesting that IEs represent a disorder of REM-sleep. An alpha(2) adrenoceptor agonist increases gripping-induced IEs, whereas alpha(2) antagonists decrease these. We have studied the effect of prazosin on IEs and the levels of alpha(1) adrenoceptors were evaluated in cerebro-cortical homogenates of taiep and control rats. Systemic administration of prazosin results in a significant increase in both the frequency and duration of gripping-induced IEs. Our results show that cerebro-cortical tissue is not an adequate candidate for the expression of cataplexy-like symptoms, but prazosin, an alpha(1) antagonist, is a potent inducer of gripping-induced immobility episodes in taiep rats.

Adrenergic alpha-1 Receptor Antagonists↗